2026 Reed Conference for Pharmacy

Artificial intelligence is rapidly moving from abstract concept to everyday tool in healthcare, and pharmacy will feel its impact acutely over the next five years. This session will move beyond basic definitions to explore how emerging AI capabilities are poised to reshape the medication-use process across community, health-system, and ambulatory care settings.

Using practical, pharmacy-focused examples, the session will review a simple mental model for how AI tools are developed, validated, and monitored, then apply it to real and near-future use cases: order verification support, dosing recommendations, risk prediction, documentation assistance, remote monitoring, and more.

The session will also introduce key considerations for evaluating AI-enabled products, including clinical relevance, performance, workflow integration, privacy, and oversight. Finally, attention will be given to how pharmacists can begin preparing for AI-enabled care, positioning the profession to engage thoughtfully and responsibly with these technologies rather than reactively responding to them.

At the completion of this activity, the participant should be able to:

• Describe key emerging AI capabilities expected to affect pharmacy practice over the next 3–5 years across pharmacy care settings.
• Explain a basic mental model for how AI tools used in medication management are developed, validated, implemented, and monitored, and relate this to the medication-use process.
• List key considerations for evaluating AI-enabled products, including clinical relevance, performance, workflow integration, privacy, and governance.

Presenter

Timothy Aungst, PharmD, is a professor of pharmacy practice at MCPHS Worcester/Manchester and a clinical pharmacist specializing in Digital health, ambulatory care, cardiometabolic and geriatric medicine. For the past decade, he has focused on how technology can enhance care, evaluating over 2,000 mobile apps and digital health products and creating frameworks to assess their clinical relevance to practice and pharmacy education. He is an expert in smart medications, digital therapeutics, digital biomarkers, and remote patient monitoring, advising systems, payers, and digital health organizations. He serves as an advisor to multiple pharmacy organizations to enable efforts to build digital health and AI standards for clinical practice and training for pharmacists.

This will be an engaging and comprehensive exploration of continuous glucose monitoring (CGM) and its transformative role in diabetes management. Designed for pharmacists across community, hospital, and ambulatory care settings, this presentation highlights the essential knowledge and practical skills needed to support patients using CGM technology. This session will demonstrate how to interpret CGM metrics, such as time in range and glucose variability, and apply them to optimize medication regimens and improve patient outcomes. Discover strategies to educate patients about CGM devices and collaborate with interdisciplinary teams to enhance diabetes care.

This session will also address patient selection criteria, discuss the benefits of continuous glucose monitoring, and examine a real-world case study to provide actionable insights. Whether you’re new to CGM or looking to deepen your expertise, this session empowers pharmacists to take a leading role in advancing diabetes management.

At the completion of this activity, the participant should be able to:

• Explain the fundamentals of continuous glucose monitoring (CGM) technology.
• Interpret CGM data for clinical decision-making.
• Recognize the pharmacist's role in supporting CGM use.
• Apply patient selection criteria for CGM use.

Presenter

Dr. Jennifer Goldman, PharmD, CDCES, BC‑ADM, FCCP, is a Professor of Pharmacy Practice at MCPHS, Boston, and Clinical Pharmacist/Director of the Cardiometabolic Program at Well Life in Peabody, MA. With 36 years of clinical experience, she is board certified in advanced diabetes management, a Certified Diabetes Care and Education Specialist, and a Fellow of the American College of Clinical Pharmacists. Dr. Goldman teaches in both pharmacy and PA programs and precepts students, residents, and fellows in chronic disease management. A nationally recognized speaker and educator, she has presented at major pharmacy and medical conferences and served on numerous public health and diabetes boards. She has published over 100 works focused on diabetes, cardiometabolic and renal disease, and pharmacy education and has earned numerous awards for excellence in scholarship, education and service.

Activity Number: 0026-0000-26-001-L01-P | Knowledge-based
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0

Because laws and regulations continually change, pharmacists may have difficulty staying up-to-date to fill prescriptions legally. The information provided in this session will help pharmacists practice within the bounds of state and federal laws and regulations. This presentation will go into great detail on these topics to assist with everyday pharmacy practice, including prescription-filling activities.

At the completion of this activity, the participant should be able to:

• Identify major changes set forth in new and updated regulations.
• Summarize key points from new and updated advisories, policies, and circular letters.
• Recognize common inspectional deficiencies.

Presenters

Michael J. Godek, RPh is the Executive Director of the Massachusetts Board of Pharmacy, overseeing licensure, regulation, and public health protections across the Commonwealth. With over 30 years of pharmacy leadership—including senior roles in community pharmacy—he has championed innovation, workforce development, and patient-centered care. He holds a U.S. patent for an Early Refill Facilitation Method and was recognized in 2021 for his leadership during the COVID-19 pandemic. Michael earned his B.S. in Pharmacy from the Massachusetts College of Pharmacy and serves in leadership roles with NABP, MPhA, APhA, MSHP, MIPA, MCPC, and ASHP. A dedicated educator and mentor, his work continues to shape the future of pharmacy practice and regulation.

Julienne Tran, PharmD, RPh is a Pharmacy Investigator with the Department of Public Health at the Board of Pharmacy. She reviews complaints and reports received from the general public and agency personnel concerning alleged violations of laws and regulations. Additionally, conducts inspections and evaluates pharmacy and drug-related practices in health care facilities and pharmacies to ensure the health and safety of patients. She also serves as an academic preceptor for Massachusetts College of Pharmacy-Boston. Julienne is a graduate of MCPHS-Boston where she received her PharmD in Pharmacy. She is currently an MBA candidate at the University of Massachusetts-Dartmouth. Julienne’s 14-year pharmacy career has focused mainly on community pharmacy. She began her career as a retail staff pharmacist and then shifted her work to the area of retail corporate as a clinical pharmacist overseeing the training and development of disease-state management programs for pharmacists in the Northeast region.

Activity Number: 0026-0000-26-003-L03-P | Knowledge-based
Topic Designator: Pharmacy Law
Contact Hours: 1.0

The purpose of this continuing education session will be to review guideline recommendations, available evidence, and practical implementation of antithrombotic strategies in Mechanical Circulatory Support (MCS), while also reviewing management strategies for bleeding and thrombotic events.

MCS is used to facilitate circulation and maintain adequate perfusion and/or oxygenation in the acute phase or long-term. In the acute inpatient setting, percutaneous devices are indicated in select patients with cardiogenic shock, respiratory failure, or undergoing percutaneous coronary intervention. In the long-term or outpatient setting, durable devices are indicated in patients with end-stage refractory heart failure, either as destination therapy or as a bridge to cardiac transplantation. While MCS may provide life-saving support, use of these devices may increase both bleeding and thrombotic potential, necessitating careful use of antithrombotic therapies and a balance of risks.

At the completion of this activity, the participant should be able to:

• Describe the mechanisms of mechanical circulatory support devices and the associated bleeding and thrombotic risks
• Evaluate available literature and guideline recommendations surrounding anticoagulation management in mechanical circulatory support
• Apply available guidance to the management of bleeding and thrombotic events with mechanical circulatory support

Presenter

Dareen Kanaan, PharmD, MPH, BCCP, Clinical Pharmacy Specialist III and the PGY2 Thrombosis and Hemostasis Management Residency Program Coordinator at Brigham and Women’s Hospital (BWH). She primarily practices in the coronary care ICU and Hemostatic and Antithrombotic Stewardship, where she precepts students and residents. She is actively involved in research, has contributed to multiple publications and has performed peer review for several journals and board recertification courses. Dareen serves on numerous department and system-wide committees and contributes to institutional guideline development. Dareen received her Doctor of Pharmacy and Master of Public Health degrees from MCPHS-Boston, and she completed post-graduate year 1 and 2 (cardiology) training at BWH.

Activity Number: 0026-0000-26-007-L01-P | Application-based
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0

This session will review key updates in menopause treatment, including the FDA’s removal of most boxed warnings from estrogen-containing hormone therapy. This session will also cover new non-hormonal options, such as the neurokinin-1 and neurokinin-3 receptor antagonists, recently approved for moderate to severe hot flashes. These advances expand choices for individualized care and improve the quality of life for patients. Participants will learn strategies for integrating these updates into clinical practice.

At the completion of this activity, the participant should be able to:

• Describe recent FDA updates regarding the removal of black box warnings from estrogen-containing hormone therapy and their implications for clinical practice.
• Identify newly approved non-hormonal therapies, including the neurokinin-1 and neurokinin-3 receptor antagonists, and evaluate their role in managing vasomotor symptoms of menopause.
• Apply evidence-based strategies to individualize menopause care, balancing benefits and risks to optimize patient outcomes.

Presenter

Aimee Dawson, PharmD, CDCES, is an Associate Professor and current Vice Chair of Pharmacy Practice for the MCPHS School of Pharmacy Worcester/Manchester. She maintains an ambulatory care practice site at Holyoke Health Center, with a focus on pharmacist-prescribed birth control and diabetes management. She serves as the pharmacist representative on a state working group aimed at implementing ACCESS and other reproductive health laws in Massachusetts.

How the Patient Safety and Quality Improvement Act Improves Patient Safety

This complimentary online module will explore the history, purpose and application of the Patient Safety and Quality Improvement Act of 2005 for the purpose of promoting patient safety. This activity will describe the role of patient safety organizations and how courts have applied Federal protections to error data disclosed. Additionally, this activity will explore state continuous quality improvement programs and how states mandate affirmative reporting duties to Boards of Pharmacy for errors committed. Lastly, the activity will delve into the concept of “Just Culture” and how certain Boards of Pharmacy apply discipline for human errors.

At the completion of this activity, the participant should be able to:

• Outline the history, purpose and application of the Patient Safety and Quality Improvement Act of 2005 for the purpose of promoting patient safety.
• Describe the role of patient safety organizations and how courts have applied Federal protections to error data disclosed.
• Explain state continuous quality improvement programs and how states mandate affirmative reporting duties to Boards of Pharmacy for errors committed.
• Discuss the concept of “Just Culture” and how certain Board of Pharmacy apply discipline for human errors.

Presenter

Joseph Lavino, PharmD, JD, AVP, is a pharmacist attorney and serves as Associate Vice President and Assistant General Counsel for CVS Health. Joe is an Adjunct Professor at Massachusetts College of Pharmacy teaching Law and Health Policy. His practice includes a wide spectrum of pharmacy regulatory matters including advising various businesses on compliance with complex pharmacy scenarios and advocacy for optimizing pharmacy practice.

Activity Number: 0026-0000-26-006-H03-P | Knowledge-based
Topic Designator: Pharmacy Law
Contact Hours: 1.0
Cost: Free of Charge